At Veeda CR, our Biologics and Biosimilars team includes Clinical Research professional, Physicians, Medical Writers, Safety Experts, Bio analytics with extensive experience in supporting development of Biosimilars for Indian and Global Registration. The team works with a focus of developing Veeda CR as a leading service provider in the field of Biologics - both novel and Biosimilars. We understand that, this class of drug provides exceptional challenges and requires in-depth knowledge and 'out of the box' thinking, which our group is capable of.
We aim to provide services at three levels. Firstly, as a CRO we will undertake to develop your Biological drug in the clinical environment which is mandated for its acceptance in the major markets of the world. At a higher level, we would aim to advise your in-house project team on the most strategic ways forward with the molecule which you have developed. This means an intense focus on the ultimate markets for which you are aiming and the customizing of the clinical trials program to meet those markets. In a perfect world, it would be possible to have one series of trials for all markets but regulatory differences between countries means, for instance, that the reference drugs may be different. In addition to the clinical trials program from Phase I to Phase III, we offer a full set of supporting capabilities within our own services. These includes large-molecule bioanalytical services, immunogenicity analysis and pharmacovigilance both pre- and post- market authorization. Finally at the highest level we aim to interact with decision makers in companies beginning to explore the possibility of entering the biological field. Selection of the right drug for the right company is important and our experienced team can guide and support pharma and biotech companies in developing portfolios based on prior experience, capability and capacity.
Veeda offers a full range of consulting, regulatory, laboratory and clinical development services to support biosimilar product development.
|Analyte||No. Samples Analyzed||No. of Samples Analyzed for ISR||% of ISR Samples within Acceptance|